Subconjunctival Hemorrhage as a Sign of Intraocular Retinoblastoma Progression to Orbital Retinoblastoma
Downloads
Introduction: Retinoblastoma is the most common intraocular malignancy of childhood. While treatable when detected early, a delayed diagnosis can lead to orbital extension, which significantly worsens the prognosis. We report an unusual case in which a subconjunctival hemorrhage signaled the progression of intraocular retinoblastoma to orbital involvement. Case Presentation: A 2-year-4-month-old child presented with a one-month history of left-eye leukocoria. Ocular ultrasound and computed tomography (CT) confirmed features of an intraocular retinoblastoma (Group E), and urgent enucleation was planned. The surgery was delayed by two months; shortly before the operation, the child developed an inferonasal subconjunctival hemorrhage that rapidly expanded. During enucleation, a reddish-brown extrascleral tumor was discovered beneath the hemorrhage, indicating orbital extension. Histopathology revealed Grade 3 retinoblastoma with optic nerve invasion (resection margin free of tumor). Adjuvant chemotherapy was initiated postoperatively. Conclusion: Subconjunctival hemorrhage can be an unusual warning sign of orbital tumor extension in retinoblastoma. This case highlights the importance of raising awareness and reducing diagnostic delays, particularly in resource-constrained settings.
Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Adamou Boubacar S, Ademola-Popoola DS, et al. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol 2020;6:685. https://doi.org/10.1001/jamaoncol.2019.6716.
Chawla B, Hada M. Orbital Retinoblastoma: Diagnosis and Management. Clinical Ophthalmic Oncology, Cham: Springer International Publishing; 2019.
Elam AR, Tseng VL, Rodriguez TM, Mike E V., Warren AK, Coleman AL, et al. Disparities in vision health and eye care. Ophthalmology 2022;129:e89–113. https://doi.org/10.1016/j.ophtha.2022.07.010.
Honavar S, Manjandavida F, Reddy VA. Orbital retinoblastoma: An update. Indian J Ophthalmol 2017;65:435. https://doi.org/10.4103/ijo.IJO_352_15.
Menon BS, Reddy SC, Maziah WM, Ham A, Rosline H. Extraocular retinoblastoma. Med Pediatr Oncol 2000;35:75–76. https://doi.org/10.1002/1096-911x(200007)35:1<75::aid-mpo13>3.0.co;2-2.
Abramson DH. Retinoblastoma: Saving life with vision. Annu Rev Med 2014;65:171–184. https://doi.org/10.1146/annurev-med-061312-123455.
Brar V, Couser N, Dhalla M, Goldman D, Kang K, Richards N, et al., editors. Fundamentals and Principles of Ophthalmology. 2023-2024 BCSC Basic and Clinical Science Course, San Francisco: American Academy of Ophthalmology; 2023.
Pedoman Nasional Pelayanan Kedokteran - Tata Laksana Retinoblastoma. Kementerian Kesehatan Republik Indonesia 2022. https://kemkes.go.id/eng/pnpk-2022---tata-laksana-retinoblastoma (accessed January 21, 2025).
Francis JH, Abramson DH, editors. Recent Advances in Retinoblastoma Treatment. Cham: Springer International Publishing; 2015.
Doz F, Khelfaoui F, Mosseri V, Validire P, Quintana E, Michon J, et al. The role of chemotherapy in orbital involvement of retinoblastoma. The experience of a single institution with 33 patients. Cancer 1994;74:722–732. https://doi.org/10.1002/1097-0142(19940715)74:2<722::AID-CNCR2820740228>3.0.CO;2-H.
Antoneli CBG, Steinhorst F, de Cássia Braga Ribeiro K, Novaes PERS, Chojniak MMM, Arias V, et al. Extraocular retinoblastoma: A 13-year experience. Cancer 2003;98:1292–1298. https://doi.org/10.1002/cncr.11647.
Goble RR, McKenzie J, Kingston JE, Plowman PN, Hungerford JL. Orbital recurrence of retinoblastoma successfully treated by combined therapy. Br J Ophthalmol 1990;74:97–98. https://doi.org/10.1136/bjo.74.2.97.
Dimaras H. Social Aspects, Advocacy and Organizations. Clinical Ophthalmic Oncology, Cham: Springer International Publishing; 2019.
Hungerford J, Kingston J, Plowman N. Orbital recurrence of retinoblastoma. Ophthalmic Paediatr Genet 1987;8:63–68. https://doi.org/10.3109/13816818709028518.
Marr B, Singh AD. Retinoblastoma: Evaluation and Diagnosis. Clinical Ophthalmic Oncology, Cham: Springer Nature Switzerland; 2024.
Copyright (c) 2025 Anas Jatikusuma, Delfitri Lutfi, Andi Cahyadi, Heriyawati

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Vision Science and Eye Health Journal by Universitas Airlangga is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The journal allows the author to hold the copyright of the article without restrictions.
The journal allows the author(s) to retain publishing rights without restrictions.
The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Share-Alike (CC BY-SA).
The Creative Commons Attribution-Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violations.